• Accueil
  • Anti-doping, sanctions for controlled substances

Anti-doping, sanctions for controlled substances

It is about a decision handed down by the FEI tribunal on 6 September 2024 relating to doping in endurance events.

In this decision of August 30, it was about a horse that was tested by a laboratory and declared positive for an illegal substance during an endurance event.

The horse BAROOD is rider in charge of Mr. Juma’ah SALEH ABU SHABAB and trainer Mr. Khalil Taisir ALSHEIKH. During the competition, the horse was tested during the event and was diagnosed positive for Phenylbutazone and Oxyphenbutazone. Phenylbutazone is a non-steroidal anti-inflammatory drug used to relieve pain, inflammation, and control fever. Oxyphenbutazone is a metabolite of phenylbutazone.

It is a priori necessary to remember that phenylbutazone and oxyphenbutazone are controlled illegal substances in the 2023 FEI List of Prohibited Substances for Equines.

By notification letter, the FEI requested a sample analysis from the RPA no later than 10 days from the date of notification. On August 12, 2024, the RPA decided to admit the violation and receive the three-month discount.

The court recalled Article 1.8.1 of the ECMR which provides that any violation of the ECM rule results in a period of ineligibility of 6 months or more, but the person responsible can receive a leave of absence of 3 months and therefore a reduction of the period of ineligibility.

Having also acknowledged the violation of the RCEEM, the EPR accepted the sanctions set out in Article 10.8.1 of the EHIC. The EPR is sentenced to a period of ineligibility of 3 months from this decision, a fine of 2,500 CHF.

 

FEI Tribunal, 6 september 2024

Vous aimerez aussi

22/07/24

Out-of Competition Doping Control: Issues and Debates

19/01/24

Stallion ownership and distribution in French and EU equestrian sport law